Pages Menu
Categories Menu

Posted by on Mar 30, 2015 in Ethics, Neurology, Pharma

Alzforum Provides Best Assessment of Biogen’s Aducanumab (BIIB037) So Far

Alzforum Provides Best Assessment of Biogen’s Aducanumab (BIIB037) So Far

Gabrielle Strobel‘s comprehensive coverage of the phase 1 study of Biogen’s aducanumab, its presentation in Nice, France, and the ensuing hullabaloo can be found here.

The most astonishing takeaway of her write-up, IMHO:

In Nice on the two days before the aducanumab presentation, prominent Alzheimer’s researchers bantered about how financial analysts were offering them hourly rates up to four figures [emphasis added] for comments immediately after the talk. Some analysts were flying in from New York City for the day.

bmartin (1082 Posts)

A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on and Twitter.